NEW YORK (GenomeWeb News) – MolecularMD today announced a licensing deal covering DDR2 mutations for lung cancer.

The Portland, Ore.-based company has obtained the rights to commercialize IP around the mutations for diagnostic, prognostic, and predictive uses. The IP is jointly owned by the Broad Institute and Dana-Farber Cancer Institute.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.